Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis

The goal of treatment of rheumatoid arthritis (RA) is to achieve remission or low disease activity. A wide range of disease-modifying antirheumatic drugs is used for the treatment of RA, including biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (JAKi). However,...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: A. O. Bobkova, A. M. Lila
Médium: Artigo
Jazyk:Russo
Vydáno: IMA-PRESS LLC 2023-07-01
Edice:Современная ревматология
Témata:
rheumatoid arthritis
biological disease-modifying antirheumatic drugs
jak inhibitors
switching
risk factors
chemokines
On-line přístup:https://mrj.ima-press.net/mrj/article/view/1436
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky